
    
      This is a phase Ib/II clinical trial. DPX-E7 is a therapeutic vaccine, intended to treat
      HPV-related head and neck, cervical or anal cancer. DPX-E7 is an investigational vaccine and
      the FDA (the U.S. Food and Drug Administration) has not approved DPX-E7 vaccine as a
      treatment for any disease.

      DPX-E7 is being tested in humans for the first time. DPX-E7 is a kind of immunotherapy that
      will make the immune system to elicit an anti-tumor response by generating CD8+ T-cells. CD8+
      T-cells play a very important role in fighting against viral infections
    
  